10X Genomics
7068 Koll Center Parkway
Suite 401
Pleasanton
California
94566
United States
Website: https://www.10xgenomics.com/careers/
Email: recruiting@10xgenomics.com
102 articles with 10X Genomics
-
10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
6/10/2021
10x Genomics, Inc. announced it is shipping its new Visium Spatial Gene Expression for FFPE assay.
-
10x Genomics to Participate in Upcoming June Investor Conferences
5/24/2021
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating virtually in the following investor conferences: William Blair 41 st Annual Growth Stock Conference Fireside Chat on Wednesday, June 2 nd at 2:20 p.m. Eastern Time/11:20 p.m. Pacific Time
-
10x Genomics Reports First Quarter 2021 Financial ResultsQ1 2021 revenue growth of 47% over prior year
5/5/2021
10x Genomics, Inc. reported financial results for the first quarter ended March 31, 2021.
-
10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference
4/29/2021
10x Genomics, Inc., announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.
-
10x Genomics to Report First Quarter Financial Results on May 5, 2021
4/8/2021
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5th, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
-
In a list of the most innovative companies in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
-
10x Genomics Expands Pleasanton Headquarters with New Facilities at Two Locations
3/9/2021
10x Genomics, Inc. announced expansion plans to support the company’s continued growth in Pleasanton across two properties.
-
10x Genomics Announces New Product Lineup and Tetramer Shop Acquisition
2/25/2021
10x Genomics, Inc. introduced its 2021-2022 product lineup during Xperience 2021, a special presentation Wednesday with an audience of nearly 2,700.
-
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience EventAcquires Tetramer Shop; Reveals Details on Upcoming Products
2/24/2021
10x Genomics, Inc. detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase with three breakout sessions corresponding to 10x’s three product platforms: Chromium Single Cell, Visium Spatial, and In Situ Analysis.
-
10x Genomics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Outlook for 2021
2/17/2021
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021.
-
10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
1/28/2021
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors”
-
10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/23/2020
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39 th Annual J.P. Morgan Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, January 11 at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10
-
10x Genomics Reports Third Quarter 2020 Financial Results
11/10/2020
10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020 Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundatio
-
10x Genomics to Participate in the Stifel 2020 Healthcare Conference
11/4/2020
10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.com About 10x Genomics 10x Ge
-
10x Genomics to Report Third Quarter Financial Results on November 10, 2020
10/13/2020
10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: w
-
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
-
10x Genomics Announces Pricing of Upsized Public Offering - Sep 11, 2020
9/11/2020
10x Genomics, Inc. announced the pricing of an upsized underwritten public offering by the Company of its Class A common stock at a price to the public of $110.00 per share, before underwriting discounts and commissions.
-
10x Genomics Announces Launch of a Follow-On Public Offering - Sep 08, 2020
9/8/2020
10x Genomics, Inc. announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company pursuant to a registration statement filed with the Securities and Exchange Commission.
-
10x Genomics Reports Second Quarter 2020 Financial Results
8/11/2020
10x Genomics, Inc. reported financial results for the second quarter ended June 30, 2020.
-
10x Genomics to Participate in the UBS Genomics 2.0 and Medtech Innovations Summit
8/6/2020
10x Genomics announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.